Issue 51, 2016

Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications

Abstract

Manganese oxide nanoparticles (MONs) have received growing attention as alternative T1 MRI contrast agents due to the association of commercial gadolinium-based contrast agents with nephrogenic systemic fibrosis. Since the seminal publication first describing the use of MONs as positive T1 contrast agents, there is an ongoing impetus to develop MONs of higher T1 signal intensity for better diagnostic efficacy. Indeed, various MON-based nanoprobe designs have been proposed, such as the employment of a mesoporous nanomaterial with MONs evenly dispersed within, or the traditional coating of a biocompatible layer onto the surface of MONs to form a core–shell configuration. Recent advances in this field also propose stimuli-responsive MONs that capitalize on an acidic dissolution or in situ reduction to release Mn2+ ions for a multi-fold increase in MRI contrast. However, the potential nanotoxicity of MONs remains a key obstacle to the clinical translation of MON-based T1 contrast agents. Due to the wide variety of functionalities and physicochemical properties of MONs, there is also a lack of consensus on the toxicological properties of MONs. In addition, the r1 relaxivity of MRI contrast agents typically decreases at higher field strength. Hence, it highlights the need to develop MON-based contrast agents with higher relaxivities. In this regard, this article aims to present a thorough review of MONs for MRI applications, with particular emphasis on their relaxivity and toxicological properties. In order to systematically review the current state-of-the-art for the development of MONs for MRI applications, the MON-based T1 contrast agents are categorized based on the structure of the nanomaterial system. Key parameters that influence the nanotoxicity of MONs are also examined while the absorption, distribution, metabolism and excretion of MON in vivo are evaluated to discern how long the nanoparticles will be present within the body, as well as to predict the organs or tissues in which they distribute.

Graphical abstract: Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications

Article information

Article type
Review Article
Submitted
18 Feb 2016
Accepted
01 May 2016
First published
10 May 2016
This article is Open Access
Creative Commons BY license

RSC Adv., 2016,6, 45462-45474

Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications

B. Y. W. Hsu, G. Kirby, A. Tan, A. M. Seifalian, X. Li and J. Wang, RSC Adv., 2016, 6, 45462 DOI: 10.1039/C6RA04421B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements